Non-traditional producers used additive manufacturing — also known as 3D printing — to deliver an estimated 38 million face shield parts, 12 million nasal swabs, 2.5 million ear savers, 241,000 mask parts and 116,000 ventilator parts between Feb. 15 and July 15, 2020, according to a report released Friday by the Food and Drug Administration.  

“The collaboration of these NTPs around the country enabled hospitals to continue testing for COVID-19 and maintain operations; enabled healthcare workers to better protect themselves using AM face shields; provided healthcare personnel with relief from the tension of N95 respirators worn endlessly through ear savers and other quality of life improvement products,” the report concludes. “…Tremendous latent capacity exists within the U.S. to quickly pivot and respond to a national crisis with AM. To harness this capacity, formal efforts must be taken to develop infrastructure enabling and directing national communication, collaboration, and creation efforts. This infrastructure will be critical to the role AM plays in future crises.”
 

Related News Articles

Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Chairperson's File
Public
Most hospitals and health systems are the largest organizations in our communities, providing critical services needed by every one of our neighbors. We take…
Headline
The AHA May 16 urged the Department of Commerce to consider tariff exceptions for critical minerals and derivative products used for medical purposes. Critical…
Headline
The AHA May 14 urged the Senate Finance Committee to take steps to strengthen the supply chain for essential pharmaceutical and other medical products. In…
Headline
The U.S. and China reached a joint agreement to temporarily reduce tariffs for 90 days, the White House announced May 12. Both countries will lower tariffs by…
Headline
AHA today submitted comments to the Department of Commerce on its Section 232 national security investigation of pharmaceutical and pharmaceutical ingredients…